Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

Evogene Ltd. (NASDAQ:EVGN) Q4 2025 Earnings Call Transcript March 5, 2026 Evogene Ltd. misses on earnings expectations. Reported EPS is $-0.61 EPS, expectations were $-0.26. Operator: Welcome to ...

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and ...

HUTCHMED divested a 45.0% equity interest in SHPL for $608.5 million in cash in April 2025, retaining a 5.0% equity interest. As a result, HUTCHMED’s share of equity in earnings of SHPL in 2025 ...

Lawmakers introduced measures this week to criminalize AI-generated impersonation, modernize NOAA’s weather radio system and ...

The deep sea is a dark, cold place. It's just a few degrees above freezing, subject to immense pressure, and beyond the reach ...

Q4 2025 earnings call recap: pemvidutide Phase III MASH plans, Phase II data, FDA status, cash runway to 2028—read now.

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutationRezatap ...

The German doctor sold her brand to Puig in January 2024, and has since taken on the role of chief product development ...

A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Playtime is over in El Segundo as a space manufacturing startup is taking over the former home of Barbie and Hot Wheels. ...